Kornimate/medical-research-clean huggingface dataset:
low doses of cholestyramine in the treatment of hyperthyroidism

Conditions: Graves Disease

Summary: the enterohepatic circulation of thyroid hormones is increased in thyrotoxicosis.bile-salt sequestrants (ionic exchange resins) bind thyroid hormones in the intestine and thereby increase their fecal excretion. based on these observations, the use of cholestyramine has been tried. the present study evaluates the effect of low doses of cholestyramine as an adjunctive therapy in the management of hyperthyroidism

the gastrointestinal tract has a role in thyroid physiology. thyroid hormone is metabolized mainly in the liver, where it is conjugated to glucurunides and sulfates. these conjugation products are then excreted in the bile. free hormones are released in the intestine and finally reabsorbed, completing the enterohepatic circulation of thyroid hormone. a very small portion of the daily production of thyroxin (t4) and triiodothyronine (t3), less than 10 percent, is excreted in the stool (1-3). in people with normal thyroid function, this pathway of t4 and t3 recirculation contributes so little to hormone availability that patients who have gastrointestinal disease or are receiving drugs that decrease t4 absorption do not have abnormal thyroid function (4). however, the thyrotoxic states are characterized by an increased enterohepatic circulation of thyroid hormones, as well as an increased urinary and fecal excretion of both conjugated and free t4 (5,6). cholestyramine, an ionic exchange resin sequesters t4 in the intestine and increases its fecal excretion. these phenomena were proven in hamsters in mid 1960s (7). experimentally, it has been shown that 50 mg of cholestyramine can bind approximately 3000 μg of t4 (8) and therefore can enhance the clearance of thyroid hormones. because of the increased enterohepatic circulation of thyroid hormones during hyperthyroidism, attempts have been made to sequester these hormones in the intestine using ionic exchange resins (9-13). cholestyramine therapy has been studied in the treatment of thyrotoxicosis as an adjunctive therapy to thionamides, and has been found to decrease thyroid hormone levels rapidly. in several trials, cholestyramine in combination with methimazole (mmi) or propylthiouracil, caused a more rapid decline in thyroid hormone levels than standard therapy with thionamides alone (9-11,13). in all of these trials, cholestyramine was dosed at 4 grams orally two to four times a day. this study was conducted to examine the efficacy of combination therapy of lower doses of cholestyramine with mmi and propranolol for treating patients with graves' hyperthyroidism.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed hyperthyroid graves' disease exclusion criteria: * if the patient had been treated previously * diabetes, kidney, or liver disease

Keywords: hyperthyroidism cholestyramine
preoperative breast magnetic resonance imaging for patients undergoing mammoplasty

Conditions: Breast Cancer

Summary: all female with operable breast cancer seeking health care at general surgery department assiut university hospitals,and decision of therapeutic mammoplasty was taken depending on clinical examination, findings on mammography and sonography, will undergo mri breast, and see if mri finding will change decision of the surgery.

* study setting: assiut university hospital, general surgery department (c unit ) * study subjects: all female with operable breast cancer seeking health care at general surgery department and decision of therapeutic mammoplasty was taken depending on clinical examination, findings on mammography and sonography. the size, number, and location of breast cancer lesions were identified on us and mammography. also size, number, location, pattern of enhancement and presence or absence of intraductal component will be evaluated by preoperative mri. the surgical plane will be decided based on us and mammography findings. the final decision will be based on mri findings. when the initial surgical decision was the same as final decision the patient will be assigned to the unchanged group. however, if the final decision differed from the initial surgical decision the patient will be assigned to the changed group.

Eligibility criteria:
inclusion criteria: * female patient with operable breast cancer (stage 1 and 2 ) patient meet the criteria of therapeutic mammoplasty exclusion criteria: * inoperable breast cancer (stage 3 and 4) breast cancer size \> 4 cm in diameter previous radiotherapy local recurrence after previous breast conservation surgery male breast cancer
telemedicine intervention to improve physical function

Conditions: Parkinson's Disease

Summary: this project is investigating whether a one-year in-home exercise program will reduce the rate of falls and improve strength and quality of life in patients with parkinson's disease.

background/rationale: parkinson's disease (pd) is the second most common neurodegenerative disease, affecting over one million americans. the cardinal clinical manifestations of pd are motoric, which limit functional mobility leading to difficulty working, caring for family members, managing a household, and overall decreased independence and quality of life (qol). a wealth of growing data indicates tremendous benefits of exercise for patients with pd. not only have exercise programs been shown to improve motor function and reduce the risk of falls, but also improve overall qol and possibly the very course of disease pathology. however, programs that involve supervision in the home of people with pd are expensive to roll out widely, and programs that involve people with pd traveling to a central site not only result in non-compliance over time because of difficulty getting to the site, but also rule out the involvement of a large number of people with pd who simply live too far from larger centers where such programs are typically established. objective: the investigators hypothesize that a one-year in-home exercise program, centered around remote, real-time instruction and supervision, will reduce the rate of falls and improve strength and qol in patients with pd. methods: the proposed study is a randomized controlled trial of a structured exercise program, evaluating effects on fall rate, physical functioning, and qol. community-dwelling people with pd will be randomized either to a group who receives structured and remote exercise instruction and supervision in real-time or a group who is taught a lifestyle exercise program. subjects will be male and female veterans with a physician diagnosis of idiopathic, typical pd, with at least 2 of 3 cardinal signs of pd, and response to dopaminergic medication. the interventions will last one year.

Eligibility criteria:
inclusion criteria: * physician diagnosis of idiopathic, typical parkinson's disease (pd) * at least 2 of 3 cardinal signs of pd * response to dopaminergic medication exclusion criteria: * angina pectoris * history of myocardial infarction within 6 months * history of ventricular dysrhythmia requiring current therapy

Keywords: parkinson disease quality of life exercise therapy
molecular and imaging studies of cardiovascular health and disease

Conditions: Healthy; Dilated Cardiomyopathy; Hypertrophic Cardiomyopathy; Ischemic Heart Disease

Summary: biobank is a program which collects biological samples, health information and imaging data from consented patients and stored them at the core facility. these information would be used to study the molecular, imaging and outcome studies of cardiovascular health and disease.

this program recruits patient from national heart centre singapore and collects their biological sample, health information and imaging data.the donated biospecimens will be stored indefinitely and used for any future research on molecular, imaging and outcome studies of cardiovascular health and disease.the same biological samples and imaging data will be obtained from consented healthy volunteers for comparison.

Eligibility criteria:
there is no inclusion/exclusion criteria except for the age limit as this is a repository program. inclusion criteria: •subject aged ≥ 16 years and ≤ 90 years. exclusion criteria: •no

Keywords: healthy volunteer dilated cardiomyopathy hypertrophic cardiomyopathy ischemic heart disease cardiovascular magnetic resonance imaging
effectiveness of dmf (dimethyl fumarate) and its impact on pros (patient reported outcomes) in treatment-naive or suboptimal ifn (interferon) or ga (glatiramer acetate) responders with rrms (improve)

Conditions: Multiple Sclerosis, Relapsing-Remitting; Relapsing-Remitting Multiple Sclerosis

Summary: the primary objective of the study is to estimate the annualized relapse rate (arr) over a 12-month period in patients with relapsing-remitting multiple sclerosis (rrms) who are treated with dimethyl fumarate (dmf) as their initial therapy (treatment-naïve), or switching from interferon (ifn) or glatiramer acetate (ga) (after suboptimal response defined as suboptimal efficacy, intolerance, or poor adherence to ifn or ga), as determined by the prescribing physician. the secondary objectives of this study in this study population are: to assess the impact of dmf over a 12 month period on patient reported outcomes (pros) and health economic related outcomes; and to evaluate additional clinical outcomes at month 12.


Eligibility criteria:
key inclusion criteria: * have access to the internet and are able to complete online assessments on a computer. * have relapsing-remitting ms and satisfy the approved therapeutic indication for dmf per the canadian product monograph. * are either treatment-naïve or being treated for rrms with ifn or ga but, per the prescribing physician, have a suboptimal response (e.g., suboptimal efficacy, intolerance, or poor adherence) to ifn or ga or have stopped treatment with ifn or ga for rrms as a result of suboptimal response within 30-60 days of enrollment. key exclusion criteria: * have major comorbid conditions that would preclude their participation in the study as determined by the prescribing physician. * have a history of malignancy. (patients with basal cell carcinoma that has been completely excised prior to study entry remain eligible.) * are receiving disease modifying therapies other than ifn or ga or have initiated treatment with a new disease modifying therapy since discontinuation of ifn or ga. note: other protocol-defined inclusion/exclusion criteria may apply.
mechanistic clinical trial of advanced imaging for crt

Conditions: Heart Failure, Systolic

Summary: this is a mechanistic clinical trial with randomization to guidance for the crt procedure using cardiac magnetic resonance (cmr) and computed tomography angiography (cta) versus a standard procedure.

at baseline, patients will have cmr, cta, echocardiography, blood testing, and cardiopulmonary exercise testing. they will also complete a heart failure questionnaire. in patients randomized to cmr guidance for the crt procedure, lv lead placement will be guided by the mri information related to scar, activation and anatomy. patients will have follow-up assessments at 6 and 12 months. there will also be clinical follow-up for survival free of appropriate icd therapies over 3 years.

Eligibility criteria:
inclusion criteria: 1. chronic systolic hf 2. lvef 35% or less 3. guideline-based class i or ii indication for crt exclusion criteria: 1. inability to provide informed consent 2. pregnancy 3. presence of metal embedded in the body due to prior accident or injury, as documented by skull films or other imaging 4. cerebral aneurysm clips 5. cochlear implants 6. other metallic implants known to be contraindications to cmr (does not include pacemakers and icds) 7. severe claustrophobia 8. acute kidney injury 9. acute renal failure or chronic kidney disease with gfr \< 45 cc/min/1.73m2 10. liver transplant 11. gadolinium allergy 12. \>10% premature ventricular contraction (pvc) burden; and 13) estimated \>10% atrial fibrillation (af) burden based on available clinical data.
montelukast in seasonal allergic rhinitis: fall 2001 study (0476-240)

Conditions: Seasonal Allergic Rhinitis

Summary: this is a study to evaluate the treatment effect of montelukast 10 mg taken in the morning, versus placebo, in patients with seasonal allergic rhinitis. loratadine is included in the study as an active control.


Eligibility criteria:
inclusion criteria: * patient has a history of seasonal allergic rhinitis that worsens during the study season * patient is a nonsmoker * patient is in good health physical and mental health exclusion criteria: * patient is hospitalized * patient is a woman who is \< 8 weeks postpartum or is breastfeeding * patient plans to move or vacation away during the study * patient has had any major surgery with in past 4 weeks * patient is a current or past abuser of alcohol or illicit drugs
adherence assessment with travalert dosing aid

Conditions: Open-angle Glaucoma; Ocular Hypertension

Summary: the purpose of the study is to compare adherence in patients on a fixed combination of travoprost 0.004%/timolol 0.5% and patients on a concomitant combination of travoprost 0.004% and timolol 0.5% using the travalert® device.


Eligibility criteria:
inclusion criteria: * diagnosis of open-angle glaucoma or ocular hypertension; * inadequate control with beta-blocker or prostaglandin monotherapy and starting therapy with travoprost 0.004% and timolol 0.05%; * intraocular pressure (iop) at the screening visit in at least one eye ≥ 19 mmhg but not exceeding 36 mmhg in either eye; * other protocol-defined inclusion criteria may apply. exclusion criteria: * females of childbearing potential currently pregnant, breastfeeding, or not taking control measures to prevent pregnancy; * not currently receiving treatment for lowering iop with beta-blockers or prostaglandin analogs; * currently on therapy or was in therapy with another investigational agent within 30 days prior to the baseline visit; * history of chronic or recurrent severe inflammatory eye disease, or history of ocular trauma within the past six (6) months, or history of ocular infection or ocular inflammation within the past three (3) months in either eye; * history of clinically significant or progressive retinal disease or history of any other severe ocular pathology in either eye that would preclude the administration of a topical prostaglandin analogue; * history of severe or serious hypersensitivity to prostaglandin drugs or their analogues, to topical or systemic beta-blockers, or to any components of the study medication; * intraocular surgery within the past six (6) months or ocular laser surgery within the past three (3) months as determined by patient history and/or examination in either eye; * any abnormality preventing reliable applanation tonometry of either eye; * best-corrected visual acuity worse than 20/30 snellen in either eye; * use of any additional topical or systemic ocular hyposensitive medication during the study; * other protocol-defined exclusion criteria may apply.

Keywords: intraocular pressure open-angle glaucoma ocular hypertension adherence compliance
autologous adipose tissue derived mesenchymal stem cells therapy for patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: two injections in total and 3 ml autologous adipose-tissue-derived stem cells(hamscs) for each injection; time-points for intervention: 1) initial injection; 2) 3 weeks following initial injection.

adipose (fat) tissue is removed by lipo-aspiration (this may take up to 40 minutes). the fat is processed on-site to isolate and obtain the mscs,then proliferate them. the suspension of the cells is injected into the knee joint under ultrasound guidance. (about 20 minutes).

Eligibility criteria:
inclusion criteria: * subjects who understand and sign the consent form for this study. * age: 40-70, males and females. * clinical diagnosis of degenerative arthritis by radiographic criteria of kellgren and lawrence. * patients who can't treat with traditional medication and need a arthroplasty. * duration of pain over grade 4(11-point numeric scale)\> 4 months. exclusion criteria: * women who are pregnant or breast feeding or planning to become pregnant during the study. * objects who administer with a anti-inflammatory drugs within 14 days prior to inclusion in the study. * history or current evidence of alcohol or drug abuse or is a recreational user of illicit drugs or prescription medications. * treatment with intra-articular injection therapy within 2 months prior to screen. * other joint diseases except degenerative arthritis : systemic or rheumatic or inflammatory chondropathy, chondrocalcinosis, hemachromatosis, inflammatory joint disease, avascular necrosis of the femoral head, paget's disease, hemophilic arthropathy, infectional arthritis, charcot's disease, villonodular synovitis, synovial chondromatosis. * positive serology for hiv-1 or hiv-2, hepatitis b (hbsag, anti-hcv-ab), hepatitis c (anti-hcv-ab) and syphilis. * serious pre-existing medical conditions like cardiovascular diseases, renal diseases, liver diseases, endocrine diseases, cancer and diabetes mellitus. * overweight expressed as body mass index (bmi) greater than 30 (obesity grade ii). * participation in another clinical trial or treatment with a different investigational product within 3 months prior to inclusion in the study. * other pathologic conditions or circumstances that difficult participation in the study according to medical criteria.
efficacy of cuminum cyminum herbal =preparation in inhibition of plaque and gingivitis.

Conditions: Chronic Gingivitis

Summary: present work was to investigate the possible efficacy of 0.2% cuminum cyminum herbal preparation as an antiplaque and antigingivitis agent when compared with chlorhexidine.

to evaluate and compare the efficacy of 0.2% cuminum cyminum herbal preparation against 0.2% chlorhexidine by various clinical parameters i.e. plaque index, gingival index and sulcus bleeding index.

Eligibility criteria:
inclusion criteria: * volunteers with minimum 20 natural teeth without restoration. * cooperative * motivated and committed to participate in the trial period. exclusion criteria: * antibiotic or anti-inflammatory therapy in previous month. * any known allergy/ hypersensitivity to any product used in trial.

Keywords: mouthwash chlorhexidine stain
mental health support for people affected by parkinson's

Conditions: Parkinson&#39;s Disease (PD)

Summary: in addition to increasingly severe physical symptoms, parkinson's can cause distressing mental health issues. these include anxiety, depression, and memory and thinking problems, caused by a combination of biological and psychological factors. they can be more disabling than physical symptoms, reduce quality of life and increase risk of mortality. they are also upsetting for family members and unpaid carers, and may necessitate transfer to institutional care. they also increase nhs costs because of expensive hospital admissions. despite this, there are few specialist mental health professionals or psychological interventions available to help people with parkinson's. this study will address this by developing an effective programme of evidence-based psychological interventions for mental health issues in parkinson's that can be easily delivered by non-experts. parkinson's mental health specialists at ucl queen square institute of neurology will work with people affected by parkinson's and non-psychology health professionals to design specialist interventions for three key mental health needs in parkinson's, targeted at distinct stages: 1. adjusting to diagnosis; empowering people to feel more in control. 2. anxiety and/or depression; using cognitive-behavioural therapy techniques to improve mood, with particular focus on parkinson's-specific concerns. 3. advanced parkinson's; helping people with parkinson's and those around them to improve management of memory and thinking problems. the research team will design companion booklets for participants, summarizing each session. the treatment will be piloted for one year. if the interventions prove beneficial to participants and are cost-effective, the resources will be made immediately available to healthcare staff across the uk to improve access to specialist psychological services.


Eligibility criteria:
all participants will be recruited from the national hospital for neurology and neurosurgery, queen square, london. inclusion criteria: 1. diagnosis of parkinson's and 1. within three years of diagnosis or 2. anxiety/depression, as judged by scores above clinical cut-offs on standardized measures or 3. developing parkinson's-related cognitive impairment/hallucinations/delusions, but retaining capacity to consent, as judged by their medical consultant. 2. aged 18 years and above 3. sufficiently fluent in english 4. able to give informed consent 5. able to attend queen square for the intervention 6. able to complete the self-report questionnaires exclusion criterion: * already participating in psychological therapy or research aimed at improving psychological wellbeing.
single-dose study to assess efficacy of canakinumab (acz885) in patients with active juvenile idiopathic arthritis (sjia)

Conditions: Systemic Juvenile Idiopathic Arthritis

Summary: this study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (sjia) having a flare. response to treatment will be according to the adapted american college of rheumatology(acr)pediatric 30 criteria at day 15.


Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of systemic juvenile idiopathic arthritis as per ilar definition that must have occurred at least 2 months prior to enrollment with onset of disease \< 16 years of age: * arthritis in one or more joints with or preceded by fever of at least 2 weeks duration that is documented to be daily/quotidian for at least 3 days and accompanied by one or more of the following: * evanescent nonfixed erythematous rash, * generalized lymph node enlargement, * hepatomegaly and/ or splenomegaly, * serositis 2. parent's or legal guardian's written informed consent and child's assent, if appropriate, or patient's informed consent for ≥ 18 years of age 3. male and female patients aged ≥ 2 to \< 20 years of age 4. active disease at the time of enrollment defined as follows: * at least 2 joints with active arthritis * documented spiking, intermittent fever (body temperature \> 38°c) for at least 1 day during the screening period within 1 week before first canakinumab/placebo dose * c-reactive protein (crp) \> 30 mg/l (normal range \< 10 mg/l) 5. naïve to canakinumab 6. other protocol defined inclusion criteria may apply exclusion criteria: patients who fulfilled one or more of the following criteria were not eligible for inclusion in this study: 1. pregnant or nursing (lactating) female patients 2. female patients having reached sexual maturity unless their career, lifestyle, or sexual orientation precluded intercourse with a male partner and/or they were using an acceptable method of contraception 3. history of hypersensitivity to study drug or to biologics. 4. diagnosis of active macrophage-activation syndrome (mas) (ravelli, magni-manzoni and pistorio 2005) within the last 6 months 5. with active or recurrent bacterial, fungal or viral infection, including patients with evidence of human immunodeficiency virus (hiv) infection, hepatitis b or hepatitis c infection 6. other protocol defined exclusion criteria may apply

Keywords: flare arthritis il-1beta antagonist systemic juvenile idiopathic arthritis juvenile rheumatoid systemic juvenile idiopathic arthritis with active flare